TABLE 4.
Baseline characteristics of the bendamustine and rituximab (BR) and the ibrutinib cohorts
| BR n = 165 (%) | ibrutinib = 162 (%) | P | |
|---|---|---|---|
| Age ≤ 70/ >70 years | 53 (32.1)/ 112 (67.9) | 53 (32.7)/ 109 (67.3) | 1.00 |
| gender Male/ Female | 106 (64.2)/ 59 (35.8) | 102 (63.0)/ 60 (37.0) | 0.90 |
| Time dx‐trx a < 36/≥36 months | 99 (60.0)/ 66 (40.0) | 69 (42.6)/ 93 (57.4) | <0.01 |
| RAI b stage 0‐2/ 3‐4 | 79 (63.2)/ 46 (36.8) | 59 (38.1)/ 96 (61.9) | <0.01 |
| del11q no/ yes | 101 (89.4)/ 12 (10.6) | 125 (87.4)/ 18 (12.6) | 0.77 |
a
Interval between diagnosis and treatment.
b
The Rai staging system was used here because it was adopted in the US cohort.